FORM PTO-1083

COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, VA 22313-1450

Docket No.: 478.1074 Date: June 16, 2006

In re application of:

David MORTON, et al.

Serial No.:

10/570,902

Filed:

March 7, 2006

For:

METHODS FOR PREPARING PHARMACEUTICAL COMPOSITIONS

Sir:

Transr	mitted h	erewith is a Supplemental Information Disclosure Statement in the above-identified application.								
[ ] [ ] [ <b>X</b> ]	Applic No fe	entity status under 37 C.F.R. 1.9 and 1.27 has been previously established. cants assert small entity status under 37 C.F.R. 1.9 and 1.27. e for additional claims is required. g fee for additional claims calculated as shown below, is required:								
[ <b>X</b> ]	[ ] Pe	ransmitted herewith are: tition for month extension under 37 C.F.R. 1.136 her: <b>Form PTO 1449 and Appendix A</b>								
[]	[ ] Fil	k(s) in the amount of <b>\$0.00</b> is/are attached to cover: ing fee for additional claims under 37 C.F.R. 1.16 tition for month extension under 37 C.F.R. 1.136 her:								
[ <b>X</b> ] -	The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0552.									
	[X]	Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by check submitted herewith.								
	[X]	Any patent application processing fees under 37 C.F.R. 1.17.  Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR 1.136.								

Cary S. Kappel, Reg. No. 36,561 DAVIDSON, DAVIDSON & KAPPEL, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018

Tel: (212) 736-1940 Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with sufficient postage to the United States Postal Service as "first class mail" in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandra, VA 22313-1450" on June 16, 2006.

DAVIDSON, DAVIDSON & KAPPEL, LLC



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of: David MORTON et al.

Serial No.: 10/570,902

Filed: March 7, 2006

For: METHODS FOR PREPARING PHARMACEUTICAL

**COMPOSITIONS** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

June 16, 2006

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56

Sir:

In accordance with the provisions of 37 C.F.R. § 1.97, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 (1 sheet) for consideration by the Examiner in connection with the examination of the above-identified patent application.

Applicants also respectfully advise the Examiner of the following co-pending U.S. patent applications and granted patent, all of which are commonly assigned to the owners of the instant application:

U.S. Patent Application Serial No. 09/000,065, "Powders Comprising Anti-adherent Materials for Use in Dry Powder Inhalers," filed June 16, 1998; issued as U.S. Patent No. 6,475,523 on November 5, 2002, listed as reference AA on the enclosed Form PTO-1449;

U.S. Patent Application Serial No. 11/054,074, "Powders Comprising Anti-adherent Materials for Use in Dry Powder Inhalers," filed February 9, 2005; published as U.S. Publication No. 2005-0152849 on July 14, 2005, listed as reference AB on the enclosed Form PTO-1449;

- U.S. Patent Application Serial No. 10/257,886, "Pharmaceutical Formulations for Dry Powder Inhalers," filed June 6, 2003; published as U.S. Publication No. 2003-0185764 on October 2, 2003, listed as reference AC on the enclosed Form PTO-1449;
- U.S. Patent Application Serial No. 10/257,790, "Formulations for Use in Inhaler Devices," filed May 5, 2003; published as U.S. Publication No. 2003-0175214 on September 18, 2003, listed as reference AD on the enclosed Form PTO-1449;
- U.S. Patent Application Serial No. 10/257,883, "Formulations for Use in Inhaler Devices," filed March 26, 2003; published as U.S. Publication No. 2003-0165436 on September 4, 2003, listed as reference AE on the enclosed Form PTO-1449;
- U.S. Patent Application Serial No. 10/312,488, "Method of Making Particles for Use in a Pharmaceutical Composition," filed March 11, 2003; published as U.S. Publication No. 2003-0162835 on August 28, 2003, listed as reference AF on the enclosed Form PTO-1449;
- U.S. Patent Application Serial No. 10/433,072, "Method of Making Particles for Use in a Pharmaceutical Composition," filed September 12, 2003; published as U.S. Publication No. 2004-0037785 on February 26, 2004, listed as reference AG on the enclosed Form PTO-1449;
- U.S. Patent Application Serial No. 10/433,185, "Pharmaceutical Compositions for Inhalation," filed September 12, 2003; published as U.S. Publication No. 2004-0047810 on March 11, 2004, listed as reference AH on the enclosed Form PTO-1449;
- U.S. Patent Application Serial No. 10/433,135, "Particles for Use in a Pharmaceutical Composition," filed November 28, 2003; published as U.S. Publication No. 2004-0071635 on April 15, 2004, listed as reference AI on the enclosed Form PTO-1449;
- U.S. Patent Application Serial No. 10/571,146, "Dry Powder Composition Comprising Co-jet Milled Particles for Pulmonary Inhalation," filed March 9, 2006;

U.S. Patent Application Serial No. 10/552,326, "Devices and Pharmaceutical Compositions for Enhancing Dosing Efficiency," filed March 20, 2006; and

U.S. Patent Application Serial No. 10/571,884, "Dry Powder Composition Comprising a

Benzodiazepine for Pulmonary Inhalation," filed March 13, 2006.

Pursuant to 37 C.F.R. § 1.98 (a)(2)(iii), the Examiner's attention is directed to Appendix A, attached hereto, which contains the following:

1) Specification and pending claims of U.S. Patent Application Serial No. 10/571,146;

2) Specification and pending claims of U.S. Patent Application Serial No. 10/552,326;

and

3) Specification and pending claims of U.S. Patent Application Serial No. 10/571,884.

It is respectfully requested that the references cited in the accompanying Form PTO-1449 (1 sheet) be considered and made of record.

The present Information Disclosure Statement is filed under 37 C.F.R. §1.97(b), before the mailing of a first Office Action on the merits. Accordingly, it is believed that no fee is due. However, if it is determined that any fee is due, the Examiner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By:

Cary S. Kappel Reg. No. 36,561

DAVIDSON, DAVIDSON & KAPPEL, LLC 485 Seventh Avenue, 14<sup>th</sup> Floor New York, NY 10018 (212) 736-1940

IUN 1 9 2006 PRENTATRADEN FORM PTO-1449 (REV. 7-80)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO.: 478.1074

FILING DATE: March 9, 2006

SERIAL NO.: 10/570,902

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): David MORTON et al.

GROUP:

							U	.S. PATENT DO	CUMENTS				
	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DAT	E RIATE
АА	6	4	7	5	5	2	3	11/05/02	Staniforth	424	070.100		
AB	20	05	01	52	8	4	9	07/14/05	Staniforth	424	489		
AC	20	03	01	85	7	6	4	10/02/03	Staniforth et al.	424	045		
AD	20	03	01_	75	2	1	4	09/18/03	Staniforth et al.	424	045		
AE	20	03	01	65	4	3	6	09/04/03	Staniforth et al.	424	045		
AF	20	03	01	62	8	3	5	08/28/03	Staniforth et al.	424	046		
AG	20	04	00	37	7	8	5	02/26/04	Staniforth et al.	424	046		
АН	20	04	00	71	6	3	5	04/15/04	Staniforth et al.	424	046		
Al	20	04	00	47	8	1	0	03/11/04	Staniforth et al.	424	046		
AJ													
AK													
AL													
AM													
AN						<u> </u>							
AO													
AP													
							FOF	REIGN PATENT (	OCUMENTS				
	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
												YES	NO
AQ													
					OTHER	PRIOR	ART (Inc	cluding Author, T	itle, Date, Pertinent Pages	, Etc.)			
AR	<u> </u>					_							
EXAMINER							DATE CONSIDERED						
	AB AC AD AE AF AG AH AI AJ AK AL AM AN AO AP	AA 6 AB 20 AC 20 AD 20 AE 20 AF 20 AG 20 AH 20 AI 20 AJ AK AL AM AN AO AP	AA 6 4  AB 20 05  AC 20 03  AD 20 03  AE 20 03  AF 20 04  AH 20 04  AI 20 04  AJ AK  AL AM  AN  AO  AP  DOCUMENT	AA 6 4 7  AB 20 05 01  AC 20 03 01  AD 20 03 01  AE 20 03 01  AF 20 03 01  AG 20 04 00  AH 20 04 00  AI 20 04 00  AJ AK  AL AM  AN  AO  AP  DOCUMENT NUMBE	AA 6 4 7 5  AB 20 05 01 52  AC 20 03 01 85  AD 20 03 01 75  AE 20 03 01 65  AF 20 03 01 62  AG 20 04 00 37  AH 20 04 00 71  AI 20 04 00 47  AJ AK  AL AM  AN  AO  DOCUMENT NUMBER	AA 6 4 7 5 5  AB 20 05 01 52 8  AC 20 03 01 85 7  AD 20 03 01 75 2  AE 20 03 01 65 4  AF 20 03 01 62 8  AG 20 04 00 37 7  AH 20 04 00 71 6  AI 20 04 00 47 8  AJ AK  AL AM  AN  AN  AO  DOCUMENT NUMBER   OTHER	AA 6 4 7 5 5 2  AB 20 05 01 52 8 4  AC 20 03 01 85 7 6  AD 20 03 01 75 2 1  AE 20 03 01 65 4 3  AF 20 03 01 62 8 3  AG 20 04 00 37 7 8  AH 20 04 00 71 6 3  AI 20 04 00 47 8 1  AJ AK  AL AM  AN  AN  AO  DOCUMENT NUMBER   OTHER PRIOR	AA 6 4 7 5 5 2 3  AB 20 05 01 52 8 4 9  AC 20 03 01 85 7 6 4  AD 20 03 01 75 2 1 4  AE 20 03 01 65 4 3 6  AF 20 03 01 62 8 3 5  AG 20 04 00 37 7 8 5  AI 20 04 00 71 6 3 5  AI 20 04 00 47 8 1 0  AJ AK AL AL AN	DATE  AA 6 4 7 5 5 2 3 11/05/02  AB 20 05 01 52 8 4 9 07/14/05  AC 20 03 01 85 7 6 4 10/02/03  AD 20 03 01 75 2 1 4 09/18/03  AE 20 03 01 65 4 3 6 09/04/03  AF 20 03 01 62 8 3 5 08/28/03  AG 20 04 00 37 7 8 5 02/26/04  AH 20 04 00 71 6 3 5 04/15/04  AI 20 04 00 47 8 1 0 0 03/11/04  AJ AK AL AL AM AN	AA 6 4 7 5 5 2 3 11/05/02 Staniforth  AB 20 05 01 52 8 4 9 07/14/05 Staniforth  AC 20 03 01 85 7 6 4 10/02/03 Staniforth et al.  AD 20 03 01 75 2 1 4 09/18/03 Staniforth et al.  AE 20 03 01 65 4 3 6 09/04/03 Staniforth et al.  AF 20 03 01 62 8 3 5 08/28/03 Staniforth et al.  AG 20 04 00 37 7 8 5 02/26/04 Staniforth et al.  AH 20 04 00 71 6 3 5 04/15/04 Staniforth et al.  AI 20 04 00 47 8 1 0 03/11/04 Staniforth et al.  AJ AK AL AL AN	DOCUMENT NUMBER	DOCUMENT NUMBER	DOCUMENT NUMBER

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.